Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ... [Yahoo! Finance]